HC Wainwright Forecasts Envoy Medical Q1 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Stock analysts at HC Wainwright issued their Q1 2027 earnings estimates for Envoy Medical in a research report issued on Wednesday, July 15th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.19) EPS.

Envoy Medical (NASDAQ:COCH) last issued its earnings results on Monday, May 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million.

A number of other brokerages also recently commented on COCH. Zacks Research upgraded Envoy Medical to a “hold” rating in a research note on Wednesday, April 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research report on Friday, April 24th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $2.50.

Envoy Medical Stock Performance

NASDAQ COCH opened at $0.72 on Thursday. The firm has a market capitalization of $55.62 million, a PE ratio of -0.72 and a beta of 1.88. Envoy Medical has a one year low of $0.36 and a one year high of $1.89. The company has a 50-day simple moving average of $0.69 and a 200-day simple moving average of $0.68.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Bancorp USA Inc. bought a new position in Envoy Medical in the 3rd quarter worth about $60,000. Geode Capital Management LLC boosted its position in Envoy Medical by 111.3% during the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after acquiring an additional 51,813 shares during the period. Focus Partners Wealth acquired a new position in Envoy Medical during the 1st quarter worth $276,000. Finally, DSG Capital Advisors LLC bought a new position in Envoy Medical in the 1st quarter valued at about $416,000. 8.59% of the stock is owned by institutional investors and hedge funds.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.